Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.
about
Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysisSystematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasisReview: analysis of parasite and other skewed countsNovel therapeutic and prevention approaches for schistosomiasis: reviewDoes calcium channel blockade have a role in prevention of expression of sepsis in renal transplant recipients?Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screeningReduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoniEfficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in childrenUtility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic reviewA multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and BrazilAntischistosomal activity of trioxaquines: in vivo efficacy and mechanism of action on Schistosoma mansoniMolecular cloning and characterization of novel glutamate-gated chloride channel subunits from Schistosoma mansoniPraziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infectionsIn silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoniDevelopment and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoniDiscovery and Characterization of Novel Anti-schistosomal Properties of the Anti-anginal Drug, Perhexiline and Its Impact on Schistosoma mansoni Male and Female Reproductive SystemsThe role of evolutionary biology in research and control of liver flukes in Southeast Asia.Phage displaying peptides mimic schistosoma antigenic epitopes selected by rat natural antibodies and protective immunity induced by their immunization in mice.Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.Schistosomiasis chemotherapy.Comparative pharmacology of flatworm and roundworm glutamate-gated chloride channels: Implications for potential anthelmintics.Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.Praziquantel efficacy against Schistosoma mansoni among HIV-1 infected and uninfected adults living in fishing villages along Lake Victoria, Northwest TanzaniaDiagnostic performance of Schistosoma real-time PCR in urine samples from Kenyan children infected with Schistosoma haematobium: day-to-day variation and follow-up after praziquantel treatment.Schistosoma mansoni population structure and persistence after praziquantel treatment in two villages of Bahia, Brazil.Evolutionary concepts in predicting and evaluating the impact of mass chemotherapy schistosomiasis control programmes on parasites and their hosts.Lysosome-associated membrane glycoprotein (LAMP)--preliminary study on a hidden antigen target for vaccination against schistosomiasisPraziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.Molecular epidemiology of Schistosoma mansoni: a robust, high-throughput method to assess multiple microsatellite markers from individual miracidia.Natural products as a source for treating neglected parasitic diseases.Microarray based analysis of temperature and oxidative stress induced messenger RNA in Schistosoma mansoni.Anti-Inflammatory Properties of Menthol and Menthone in Schistosoma mansoni Infection.Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in miceNew approaches for understanding mechanisms of drug resistance in schistosomesPrevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.Advances in the discovery and development of trematocidal drugs.Parasitic infections in travelers and immigrants: part II helminths and ectoparasites.Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire.Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda.
P2860
Q21198915-C642E84A-3939-4C00-A558-7C7ABE48E33EQ21560762-44A0B14E-0950-45DF-B168-B3F299AB6B21Q26864243-105CDF19-6BE9-470A-87B8-D731B3BB9B9DQ27008897-503A9277-8A41-4937-855E-C1220976F75CQ28068687-224B1D31-811D-4763-ADED-B9AA2B65279DQ28475069-192BB0AD-9D0F-42AC-99F9-8D2793326B11Q28475935-BEB6C40C-516D-4CC7-BA8B-12D8FC90B33DQ28476262-0ECF8B5B-0C18-41A9-A06E-07B8C68E6555Q28477145-FF71141C-8689-49C7-8D58-707DB105E79AQ28478552-40C8C1AD-6BF1-4865-BE99-C9A4E382E276Q28480620-315A6A54-8A14-49FE-A1CD-FFEC80627BAEQ28536093-3A821BFB-FCF5-4338-B25E-3C2CF2139FD0Q28537753-E878C8C1-757A-49B6-B23F-4FB75E4635F7Q28542999-35ABDF3D-DCAE-4341-96ED-442DB8A164A6Q28543164-EBD1FB0E-331A-4585-977E-97A5767E46A6Q28553478-14663E9E-27BF-4917-82F8-6ABEA6D3658FQ30250267-B67789FE-63E2-4022-B131-B8930617F577Q33215338-42E85C97-BBBA-4F9C-BDC0-DC83AD972A5CQ34139634-5A818B94-1B87-4129-B1CC-BD971470E88EQ34354490-CB92D38D-CFA7-4822-AB57-5F5D30A6C9CEQ34705499-D7739895-5920-4813-A0B7-D029AD22C0ACQ34939414-16070F94-0A87-457B-9B9A-73AAE9B3DD5BQ35066116-EA409F1D-57C4-45BA-8F0E-E2189127AC6DQ35151827-89B6AB4C-A3D2-4676-BC97-2FC5F0C51641Q35163069-2B830EA9-049A-4797-AE73-D4E50C7BB50BQ35960717-BDAE3E6B-6A0E-4D3B-832E-D7FB5241BFE8Q36168215-52B1AFAB-E606-4D5E-B692-DFE98D720FDFQ36441487-7AA9C552-3E7B-43D7-9D62-016161B9C94FQ36515544-81EA4199-1EF2-4337-8622-83C1D95F5177Q36656087-649E35D2-1D87-4179-AD7B-2D0E4AC206E3Q36990847-EBE758EF-E269-46B8-AFB0-62266E214A84Q37015972-CC3F7A54-A20E-4D4F-BFA5-30DA928E4B71Q37053148-51A46256-0E07-4157-AECD-1F52ADD15850Q37177725-02A01F97-31A9-47DC-8E11-AF66182309C9Q37360021-5444A7A5-FD8B-4E78-9F9D-C98F4B057794Q37413446-9EE3582B-BC72-438C-B2DA-7F7F251843DBQ38089167-E6367D70-054A-4AA5-980E-D379D69E63A9Q38322755-853C3FFE-0858-46D4-AF3B-A1C5B22B2C2DQ38452685-2C407F7E-FA5F-43C7-B5D6-80C582C3D1FCQ38452776-838EF3C8-7073-477F-8408-917B9BE2C3D7
P2860
Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Are poor responses to praziqua ...... ? An overview of the evidence.
@en
Are poor responses to praziqua ...... ? An overview of the evidence.
@nl
type
label
Are poor responses to praziqua ...... ? An overview of the evidence.
@en
Are poor responses to praziqua ...... ? An overview of the evidence.
@nl
prefLabel
Are poor responses to praziqua ...... ? An overview of the evidence.
@en
Are poor responses to praziqua ...... ? An overview of the evidence.
@nl
P2093
P2860
P1476
Are poor responses to praziqua ...... e? An overview of the evidence
@en
P2093
B Gryseels
F F Stelma
L A Tchuem-Tchuenté
L Van Lieshout
P2860
P304
P356
10.1046/J.1365-3156.2001.00811.X
P577
2001-11-01T00:00:00Z